Caris Life Sciences, Inc.
CAI
$18.81
$0.341.84%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Net Income | 321.82% | 135.92% | -8.47% | 7.61% | |
| Total Depreciation and Amortization | -52.67% | -53.76% | -44.80% | -60.21% | |
| Total Amortization of Deferred Charges | -68.26% | 34.88% | 347.75% | 22.33% | |
| Total Other Non-Cash Items | 384.76% | 508.32% | 1,212.36% | 157.65% | |
| Change in Net Operating Assets | -748.11% | 183.86% | 65.05% | 1,225.08% | |
| Cash from Operations | 215.05% | 189.91% | 111.58% | 57.61% | |
| Capital Expenditure | -122.27% | -288.13% | 46.45% | -54.72% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -- | -- | -- | -- | |
| Cash from Investing | -122.27% | -288.13% | 46.45% | -104.51% | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -85.71% | 11.54% | 26.67% | 72.50% | |
| Issuance of Common Stock | 1,319.85% | 75.73% | 134,670.74% | 582.86% | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -- | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | 100.00% | -945.20% | 980.08% | -- | |
| Cash from Financing | 1,403.98% | -24,349.43% | 528,318.60% | -99.36% | |
| Foreign Exchange rate Adjustments | -2,800.00% | 487.50% | 675.00% | 300.00% | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | 205.06% | 148.18% | 1,147.37% | -117.62% | |